One Hundred Courses of Cluster Maintenance Transcranial Magnetic Stimulation (CM TMS)-A Clinical Audit Study
Affiliations
Affiliations
- Pridmore, Discipline of Psychiatry, University of Tasmania, Hobart, Tasmania, Australia; TMS Unit, Saint Helens Private Hospital, Hobart, Tasmania, Australia.
- O'Reilly, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
- Naguy, Al-Manara CAP Center, Kuwait Centre for Mental Health, Shuwaikh, State of Kuwait.
- Morey, TMS Unit, Saint Helens Private Hospital, Hobart, Tasmania, Australia.
- Turnier-Shea, TMS Unit, Saint Helens Private Hospital, Hobart, Tasmania, Australia.
- Rybak, TMS Unit, Saint Helens Private Hospital, Hobart, Tasmania, Australia.
27 October 2022
Abstract
Objective: Major depressive disorder (MDD) which comes to transcranial magnetic stimulation (TMS) is prone to relapse. Cluster maintenance (CM) TMS is courses of 5 treatments delivered over 2.5-5 days, separated by monthly or greater non-treatment periods. Our aim was to characterize the outcomes of 100 courses of CM TMS.
Method: This was a Quality Assurance/Clinical Audit study. We studied consecutive CM TMS courses provided to private hospital inpatients. Mood was rated (on admission and discharge) using the six-item Hamilton depression rating (HAMD6) and the Clinical Global Impression - Severity (CGI-S) scales. We also applied recent STAR*D criteria which are designed to measure the 'clinical change' expected to impact patient function [16].
Results: For the total sample, using the HAMD6, 83% of courses featured relapse or partial relapse on admission, and 81% featured remission on discharge. Of 46 courses featuring HAMD6 relapse on admission, 74% featured remission on discharge. For the 100 courses the HAMD6 discharge scores were significantly lower than the admission scores (p = 2.0 × 10-24), as were the CGI-S scores (p = 1.8 × 10-25). Using STAR*D criteria for people in relapse or partial relapse on admission, CM TMS provided least a 'clinically meaningful' outcome in 82% of the cases.
Conclusion: For courses featuring relapse or partial relapse on admission, CM TMS converted greater than 70% to remission at discharge. It produced statistically significant reductions in HAMD6 and CGI-S scores, and using STAR*D criteria, at least 'clinically meaningful' change was extensively demonstrated. This evidence indicates CM TMS should be readily available to people living with relapsing MDD.
Keywords: maintenance treatment; major depressive disorder; relapse; remission; transcranial magnetic stimulation.
Similar articles
Pridmore S, Rybak M, Morey R, May T.Australas Psychiatry. 2021 Apr;29(2):218-221. doi: 10.1177/1039856220946606. Epub 2020 Aug 10.PMID: 32772718
Early relapse (ER) transcranial magnetic stimulation (TMS) in treatment resistant major depression.
Pridmore S, Erger S, Rybak M, Kelly E, May T.Brain Stimul. 2018 Sep-Oct;11(5):1098-1102. doi: 10.1016/j.brs.2018.05.013. Epub 2018 May 22.PMID: 29805096
Pridmore S, Erger S, May T.Malays J Med Sci. 2019 May;26(3):102-109. doi: 10.21315/mjms2019.26.3.8. Epub 2019 Jun 28.PMID: 31303854 Free PMC article.
Chang J, Chu Y, Ren Y, Li C, Wang Y, Chu XP.Int J Physiol Pathophysiol Pharmacol. 2020 Oct 15;12(5):128-133. eCollection 2020.PMID: 33224435 Free PMC article. Review.
Novel Augmentation Strategies in Major Depression.
Martiny K.Dan Med J. 2017 Apr;64(4):B5338.PMID: 28385173 Review.